The pharmacology of latent inhibition and its relevance to schizophrenia

Latent Inhibition: Cognition, Neuroscience and Applications to Schizophrenia

Volumn 9780521517331, Issue , 2010, Pages 276-318

  Weiner, Ina ^a   Arad, Michal ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79951857245     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511730184.014     Document Type: Chapter

References (240)

1. Abi-Dargham, A., Gil, R., Krystal, J., et al. (1998). Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. American Journal of Psychiatry, 155, 761-767.
2. Aguado, L., San Antonio, A., Perez, L., del Valle, R., & Gomez, J. (1994). Effects of the NMDA receptor antagonist ketamine on flavor memory: conditioned aversion, latent inhibition, and habituation of neophobia. Behavioral and Neural Biology, 61, 271-281.
3. Andersen, M. B., Werge, T., & Fink-Jensen, A. (2007). The acetylcholinesterase inhibitor galantamine inhibits d-amphetamine-induced psychotic-like behavior in Cebus monkeys. The Journal of Pharmacology and Experimental Therapeutics, 321, 1179-1182.
4. Angrist, B., Peselow, E., Rubinstein, M., Corwin, J., & Rotrosen, J. (1982). Partial improvement in negative schizophrenic symptoms after amphetamine. Psychopharmacology (Berl.), 78, 128-130.
5. Arnt, J., & Skarsfeldt, T. (1998). Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology, 18, 63-101.
6. Bakshi, V. P., Swerdlow, N. R., & Geyer, M. A. (1994). Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. The Journal of Pharmacology and Experimental Therapeutics, 271, 787-794.
7. Barak, S., Arad, M., De Levie, A., et al. (2009). Pro-cognitive and antipsychotic efficacy of the alpha7 nicotinic partial agonist SSR180711 in pharmacological and neurodevelopmental latent inhibition models of schizophrenia. Neuropsychopharmacology, 34, 1753-1763.
8. Barak, S., & Weiner, I. (2007). Scopolamine induces disruption of latent inhibition which is prevented by antipsychotic drugs and an acetylcholinesterase inhibitor. Neuropsychopharmacology, 32, 989-999.
9. Barak, S., & Weiner, I. (2009). Towards an animal model of an antipsychotic drug-resistant cognitive impairment in schizophrenia: scopolamine induces abnormally persistent latent inhibition, which can be reversed by cognitive enhancers but not by antipsychotic drugs. The International Journal of Neuropsychopharmacology, 12, 227-241.
10. Barak, S., & Weiner, I. (2010). Differential role of muscarinic transmission within the entorhinal cortex and basolateral amygdala in the processing of irrelevant stimuli. Neuropsychopharmacology, Jan 13. [Epub ahead of print].
11. Barrett, S. L., Bell, R., Watson, D., & King, D. J. (2004). Effects of amisulpride, risperidone and chlorpromazine on auditory and visual latent inhibition, prepulse inhibition, executive function and eye movements in healthy volunteers. Journal of Psychopharmacology, 18, 156-172.
12. Baruch, I., Hemsley, D. R., & Gray, J. A. (1988a). Differential performance of acute and chronic schizophrenics in a latent inhibition task. The Journal of Nervous and Mental Disease, 176, 598-606.
13. Baruch, I., Hemsley, D. R., & Gray, J. A. (1988b). Latent inhibition and 'psychotic proneness' in normal subjects. Personality and Individual Differences, 9, 777-783.
14. Bernstein, H. G., Bogerts, B., & Keilhoff, G. (2005). The many faces of nitric oxide in schizophrenia. A review. Schizophrenia Research, 78, 69-86.
15. Bethus, I., Muscat, R., & Goodall, G. (2006). Dopamine manipulations limited to preexposure are sufficient to modulate latent inhibition. Behavioral Neuroscience, 120, 554-562.
16. Bianchetti, A., Ranieri, P., Margiotta, A., & Trabucchi, M. (2006). Pharmacological treatment of Alzheimer's disease. Aging Clinical and Experimental Research 18, 158-162.
17. Biton, B., Bergis, O. E., Galli, F., et al. (2007). SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (1) binding and functional profile. Neuropsychopharmacology, 32, 1-16.
18. Black, M. D., Selk, D. E., Hitchcock, J. M., Wettstein, J. G., & Sorensen, S. M. (1999). On the effect of neonatal nitric oxide synthase inhibition in rats: a potential neurodevelopmental model of schizophrenia. Neuropharmacology, 38, 1299-1306.
19. Black, M. D., Simmonds, J., Senyah, Y., & Wettstein, J. G. (2002). Neonatal nitric oxide synthase inhibition: social interaction deficits in adulthood and reversal by antipsychotic drugs. Neuropharmacology, 42, 414-420.
20. Black, M. D., Varty, G. B., Arad, M., et al. (2009). Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat. Psychopharmacology (Berl.), 202, 385-396.
21. Bleuler, M. (1911). Dementia Praecox or the Group of Schizophrenias. New York: International Universities Press.
22. Bolshakov, K. V., Gmiro, V. E., Tikhonov, D. B., & Magazanik, L. G. (2003). Determinants of trapping block of N-methyl-d-aspartate receptor channels. Journal of Neurochemistry, 87, 56-65.
23. Boulay, D., Pichat, P., Dargazanli, G., et al. (2008). Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia. Pharmacology, Biochemistry, and Behavior, 91, 47-58.
24. Braunstein-Bercovitz, H., & Lubow, R. E. (1998). Are high-schizotypal normal participants distractible or limited in attentional resources? A study of latent inhibition as a function of masking task load and schizotypy level. Journal of Abnormal Psychology, 107, 659-670.
25. Breier, A., & Berg, P. H. (1999). The psychosis of schizophrenia: prevalence, response to atypical antipsychotics, and prediction of outcome. Biological Psychiatry, 46, 361-364.
26. Breier, A., Su, T. P., Saunders, R., et al. (1997). Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proceedings of the National Academy of Sciences of the United States of America, 94, 2569-2574.
27. Broen, W.E. (1968). Schizophrenia: Research and Theory. New York: Academic Press.
28. Broersen, L. M., Feldon, J., & Weiner, I. (1999). Dissociative effects of apomorphine infusions into the medial prefrontal cortex of rats on latent inhibition, prepulse inhibition and amphetamine-induced locomotion. Neuroscience, 94, 39-46.
29. Brousseau, G., Rourke, B. P., & Burke, B. (2007). Acetylcholinesterase inhibitors, neuropsychiatric symptoms, and Alzheimer's disease subtypes: an alternate hypothesis to global cognitive enhancement. Experimental and Clinical Psychopharmacology, 15, 546-554.
30. Buchanan, R.W., Javitt, D. C., Marder, S. R., et al. (2007). The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. American Journal of Psychiatry, 164, 1593-1602.
31. Bymaster, F. P., Felder, C., Ahmed, S., & McKinzie, D. (2002). Muscarinic receptors as a target for drugs treating schizophrenia. Current Drug Targets. CNS and Neurological Disorders, 1, 163-181.
32. Carlsson, A., Waters, N., & Carlsson, M. L. (1999). Neurotransmitter interactions in schizophrenia - therapeutic implications. Biological Psychiatry, 46, 1388-1395.
33. Carlsson, M., & Carlsson, A. (1990). Schizophrenia: a subcortical neurotransmitter imbalance syndrome? Schizophrenia Bulletin, 16, 425-432.
34. Carnicella, S., Pain, L., & Oberling, P. (2005). Cholinergic effects on fear conditioning I: the degraded contingency effect is disrupted by atropine but reinstated by physostigmine. Psychopharmacology (Berl.), 178, 524-532.
35. Carpenter, W. T., Jr., Heinrichs, D. W., & Alphs, L. D. (1985). Treatment of negative symptoms. Schizophrenia Bulletin, 11, 440-452.
36. Carpenter, W. T., Jr., Heinrichs, D.W., & Wagman, A. M. (1988). Deficit and nondeficit forms of schizophrenia: the concept. American Journal of Psychiatry, 145, 578-583.
37. Carpenter, W. T., & Koenig, J. I. (2008). The evolution of drug development in schizophrenia: past issues and future opportunities. Neuropsychopharmacology, 33, 2061-2079.
38. Cassaday, H. F., Hodges, H., & Gray, J. A. (1993). The effects of ritanserin, RU 24969 and 8-OH-DPAT on latent inhibition in the rat. Psychopharmacology, 7, 63-71.
39. Chagas-Martinich, L., Carey, R. J., & Carrera, M. P. (2007). 7-OH-DPAT effects on latent inhibition: low dose facilitation but high dose blockade: Implications for dopamine receptor involvement in attentional processes. Pharmacology, Biochemistry, and Behavior, 86, 441-448.
40. Chamberlain, S. R., Blackwell, A. D., Fineberg, N. A., Robbins, T.W.,&Sahakian, B. J. (2005). The neuropsychology of obsessive compulsive disorder: the importance of failures in cognitive and behavioural inhibition as candidate endophenotypic markers. Neuroscience and Biobehavioral Reviews, 29, 399-419.
41. Chang, T., Meyer, U., Feldon, J., & Yee, B. K. (2007). Disruption of the US preexposure effect and latent inhibition in two-way active avoidance by systemic amphetamine in C57BL/6 mice. Psychopharmacology (Berl.), 191, 211-221.
42. Chen, K. C., Baxter, M. G., & Rodefer, J. S. (2004). Central blockade of muscarinic cholinergic receptors disrupts affective and attentional set-shifting. The European Journal of Neuroscience, 20, 1081-1088.
43. Clarke, L. A., Cassidy, C. W., Catalano, G., Catalano, M. C., & Carroll, K.M. (2004). Psychosis induced by smoking cessation clinic administered anticholinergic overload. Annals of Clinical Psychiatry 16, 171-175.
44. Cohen, E., Sereni, N., Kaplan, O., et al. (2004). The relation between latent inhibition and symptom-types in young schizophrenics. Behavioural Brain Research, 149, 113-122.
45. Crider, A. (1997). Perseveration in schizophrenia. Schizophrenia Bulletin, 23, 3-74.
46. Csernansky, J. G., Martin, M., Shah, R., et al. (2005). Cholinesterase inhibitors ameliorate behavioral deficits induced by MK-801 in mice. Neuropsychopharmacology, 30, 2135-2143.
47. Dall'Olio, R., & Gandolfi, O. (1993). The NMDA positive modulator D-cycloserine potentiates the neuroleptic activity of D1 and D2 dopamine receptor blockers in the rat. Psychopharmacology (Berl.), 110, 165-168.
48. Dao-Castellana, M. H., Paillere-Martinot, M. L., Hantraye, P., et al. (1997). Presynaptic dopaminergic function in the striatum of schizophrenic patients. Schizophrenia Research, 23, 167-174.
49. De Levie, A., & Weiner, I. (2007a). Behavioral and pharmacological changes after neonatal nitric oxide inhibition: a model of negative symptoms. European Neuropsychopharmacology, 17(supp 4), S262.
50. De Levie, A., & Weiner, I. (2007b). Perseverative behavior after neonatal nitric oxide blockade is alleviated following enhanced NMDA but not DA function. European Neuropsychopharmacology, 17(supp 1), S60.
51. Della Casa, V., Hofer, I., Weiner, I., & Feldon, J. (1999). Effects of smoking status and schizotypy on latent inhibition. Journal of Psychopharmacology, 13, 45-57.
52. Depoortere, R., Dargazanli, G., Estenne-Bouhtou, G., et al. (2005). Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic. Neuropsychopharmacology, 30, 1963-1985.
53. Dunn, L. A., Atwater, G. E., & Kilts, C. D. (1993). Effects of antipsychotic drugs on latent inhibition: sensitivity and specificity of an animal behavioral model of clinical drug action. Psychopharmacology (Berl.), 112, 315-323.
54. Escobar, M., Oberling, P., & Miller, R. R. (2002). Associative deficit accounts of disrupted latent inhibition and blocking in schizophrenia. Neuroscience and Biobehavioral Reviews, 26, 203-216.
55. Everitt, B. J., & Robbins, T. W. (1997). Central cholinergic systems and cognition. Annual Review of Psychology, 48, 649-684.
56. Feldon, J., Shofel, A., & Weiner, I. (1991). Latent inhibition is unaffected by direct dopamine agonists. Pharmacology, Biochemistry, and Behavior, 38, 309-314.
57. Feldon, J., & Weiner, I. (1991). The latent inhibition model of schizophrenic attention disorder. Haloperidol and sulpiride enhance rats' ability to ignore irrelevant stimuli. Biological Psychiatry, 29, 635-646.
58. Friedman, J. I. (2004). Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists. Psychopharmacology (Berl.), 174, 45-53.
59. Frith, C. D. (1979). Consciousness, information processing and schizophrenia. The British Journal of Psychiatry, 134, 225-235.
60. Gaisler-Salomon, I., Diamant, L., Rubin, C., & Weiner, I. (2008). Abnormally persistent latent inhibition induced by MK801 is reversed by risperidone and by positive modulators of NMDA receptor function: differential efficacy depending on the stage of the task at which they are administered. Psychopharmacology (Berl.), 196, 255-267.
61. Gaisler-Salomon, I., & Weiner, I. (2003). Systemic administration of MK-801 produces an abnormally persistent latent inhibition which is reversed by clozapine but not haloperidol. Psychopharmacology (Berl.), 166, 333-342.
62. Gal, G., Barnea, Y., Biran, L., et al. (2009). Enhancement of latent inhibition in patients with chronic schizophrenia. Behavioural Brain Research, 197, 1-8.
63. Goff, D. C., Herz, L., Posever, T., et al. (2005). A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology (Berl.), 179, 144-150.
64. Goff, D. C., Tsai, G., Manoach, D. S., & Coyle, J. T. (1995). Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. American Journal of Psychiatry, 152, 1213-1215.
65. Gopel, C., Laufer, C., & Marcus, A. (2002). Three cases of angel's trumpet teainduced psychosis in adolescent substance abusers. Nordic Journal of Psychiatry, 56, 49-52.
66. Gosselin, G., Oberling, P., & Di Scala, G. (1996). Antagonism of amphetamineinduced disruption of latent inhibition by the atypical antipsychotic olanzapine in rats. Behavioural Pharmacology, 7, 820-826.
67. Goto, Y., & Grace, A. A. (2007). The dopamine system and the pathophysiology of schizophrenia: a basic science perspective. International Review of Neurobiology. 78C, 41-68.
68. Grace, A. A. (1991). Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience, 41, 1-24.
69. Gracey, D. J., Bell, R., & King, D. J. (2002). Differential effects of the CCKA receptor ligands PD-140,548 and A-71623 on latent inhibition in the rat. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 26, 497-504.
70. Granacher, R. P., & Baldessarini, R. J. (1975). Physostigmine. Its use in acute anticholinergic syndrome with antidepressant and antiparkinson drugs. Archives of General Psychiatry, 32, 375-380.
71. Gray, J. A., Feldon, J., Rawlins, J. N. P., Hemsley, D. R., & Smith, A. D. (1991). The neuropsychology of schizophrenia. Behavioral and Brain Sciences, 14, 1-20.
72. Gray, J. A., Moran, P. M., Grigoryan, G., et al. (1997). Latent inhibition: the nucleus accumbens connection revisited. Behavioural Brain Research, 88, 27-34.
73. Gray, J. A., & Roth, B. L. (2007). The pipeline and future of drug development in schizophrenia. Molecular Psychiatry, 12, 904-922.
74. Gray, N. S., Hemsley, D. R., & Gray, J. A. (1992). Abolition of latent inhibition in acute, but not chronic schizophrenics. Neurology Psychiatry and Brain Research, 1, 83-89.
75. Gray, N. S., Pickering, A. D., Hemsley, D. R., Dawling, S., & Gray, J. A. (1992). Abolition of latent inhibition by a single 5 mg dose of d-amphetamine in man. Psychopharmacology (Berl.), 107, 425-430.
76. Gray, N. S., Pilowsky, L. S., Gray, J. A., & Kerwin, R. W. (1995). Latent inhibition in drug naive schizophrenics: relationship to duration of illness and dopamine D2 binding using SPET. Schizophrenia Research, 17, 95-107.
77. Guillin, O., Abi-Dargham, A., & Laruelle, M. (2007). Neurobiology of dopamine in schizophrenia. International Review of Neurobiology, 78, 1-39.
78. Hajos, M., Hurst, R. S., Hoffmann, W. E., et al. (2005). The selective alpha7 nicotinic acetylcholine receptor agonist PNU-282987 [N-[(3R)-1-Azabicyclo[2.2.2]oct- 3-yl]-4-chlorobenzamide hydrochloride] enhances GABAergic synaptic activity in brain slices and restores auditory gating deficits in anesthetized rats. The Journal of Pharmacology and Experimental Therapeutics, 312, 1213-1222.
79. Harsing, L. G., Jr., Gacsalyi, I., Szabo, G., et al. (2003). The glycine transporter-1 inhibitors NFPS and Org 24461: a pharmacological study. Pharmacology, Biochemistry, and Behavior, 74, 811-825.
80. Harvey, P. D., Rabinowitz, J., Eerdekens, M., & Davidson, M. (2005). Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. The American Journal of Psychiatry, 162, 1888-1895.
81. Hashimoto, K., Koike, K., Shimizu, E., & Iyo, M. (2005). Alpha7 nicotinic receptor agonists as potential therapeutic drugs for schizophrenia. Current Medicinal Chemistry Central Nervous System Agents, 5, 171.
82. Hasselmo, M. E., & McGaughy, J. (2004). High acetylcholine levels set circuit dynamics for attention and encoding and low acetylcholine levels set dynamics for consolidation. Progress in Brain Research, 145, 207-231.
83. Hietala, J., Syvalahti, E., Vilkman, H., et al. (1999). Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia. Schizophrenia Research, 35, 41-50.
84. Hoehn-Saric, R., McLeod, D. R., & Glowa, J. R. (1991). The effects of NMDA receptor blockade on the acquisition of a conditioned emotional response. Biological Psychiatry, 30, 170-176.
85. Hohnadel, E., Bouchard, K., & Terry, A. V., Jr. (2007). Galantamine and donepezil attenuate pharmacologically induced deficits in prepulse inhibition in rats. Neuropharmacology, 52, 542-551.
86. Hyde, T.M., & Crook, J. M. (2001). Cholinergic systems and schizophrenia: primary pathology or epiphenomena? Journal of Chemical Neuroanatomy, 22, 53-63.
87. Ichikawa, J., Chung, Y. C., Li, Z., Dai, J., & Meltzer, H. Y. (2002). Cholinergic modulation of basal and amphetamine-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Brain Research, 958, 176-184.
88. Ikemoto, S., & Panksepp, J. (1999). The role of nucleus accumbens dopamine in motivated behavior: a unifying interpretation with special reference to reward-seeking. Brain Research. Brain Research Reviews, 31, 6-41.
89. Javitt, D. C. (2002). Glycine modulators in schizophrenia. Current Opinion in Investigational Drugs, 3, 1067-1072.
90. Javitt, D. C. (2008). Glycine transport inhibitors and the treatment of schizophrenia. Biological Psychiatry, 63, 6-8.
91. Javitt, D. C., Balla, A., Sershen, H., & Lajtha, A. (1999). Reversal of phencyclidineinduced effects by glycine and glycine transport inhibitors. Biological Psychiatry, 45, 668-679.
92. Javitt, D. C., Sershen, H., Hashim, A., & Lajtha, A. (1997). Reversal of phencyclidine-induced hyperactivity by glycine and the glycine uptake inhibitor glycyldodecylamide. Neuropsychopharmacology, 17, 202-204.
93. Javitt, D. C., & Zukin, S. R. (1991). Recent advances in the phencyclidine model of schizophrenia. The American Journal of Psychiatry, 148, 1301-1308.
94. Jentsch, J. D., & Roth, R. H. (1999). The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology, 20, 201-225.
95. Jentsch, J. D., & Taylor, J. R. (2001). Impaired inhibition of conditioned responses produced by subchronic administration of phencyclidine to rats. Neuropsychopharmacology, 24, 66-74.
96. Jones, C. K., Eberle, E. L., Shaw, D. B., McKinzie, D. L., & Shannon, H. E. (2005). Pharmacologic interactions between the muscarinic cholinergic and dopaminergic systems in the modulation of prepulse inhibition in rats. The Journal of Pharmacology and Experimental Therapeutics, 312, 1055-1063.
97. Jones, C. K., & Shannon, H. E. (2000). Muscarinic cholinergic modulation of prepulse inhibition of the acoustic startle reflex. The Journal of Pharmacology and Experimental Therapeutics, 294, 1017-1023.
98. Joseph, M. H., Peters, S. L., & Gray, J. A. (1993). Nicotine blocks latent inhibition in rats: evidence for a critical role of increased functional activity of dopamine in the mesolimbic system at conditioning rather than pre-exposure. Psychopharmacology (Berl.), 110, 187-192.
99. Joseph, M. H., Peters, S. L., Moran, P.M., et al. (2000). Modulation of latent inhibition in the rat by altered dopamine transmission in the nucleus accumbens at the time of conditioning. Neuroscience, 101, 921-930.
100. Kane, J. M. (1995). Current problems with the pharmacotherapy of schizophrenia. Clinical Neuropharmacology. 18, S154-S161.
101. Kaplan, O., Dar, R., Rosenthal, L., et al. (2006). Obsessive-compulsive disorder patients display enhanced latent inhibition on a visual search task. Behaviour Research and Therapy, 44, 1137-1145.
102. Kapur, S. (2003). Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. The American Journal of Psychiatry, 160, 13-23.
103. Karan, R. S., Ravishankar, P., & Pandhi, P. (2000). Effect of muscarinic receptor agonists on animal models of psychosis. Methods and Findings in Experimental and Clinical Pharmacology, 22, 169-172.
104. Karnath, H. O., & Wallesch, C. W. (1992). Inflexibility of mental planning: a characteristic disorder with prefrontal lobe lesions? Neuropsychologia, 30, 1011-1016.
105. Kato, K., Shishido, T., Ono, M., et al. (2001). Glycine reduces novelty- and methamphetamine-induced locomotor activity in neonatal ventral hippocampal damaged rats. Neuropsychopharmacology, 24, 330-332.
106. Killcross, A. S., Dickinson, A., & Robbins, T.W. (1994a). Amphetamine-induced disruptions of latent inhibition are reinforcer mediated: implications for animal models of schizophrenic attentional dysfunction. Psychopharmacology (Berl.), 115, 185-195.
107. Killcross, A. S., Dickinson, A., & Robbins, T. W. (1994b). Effects of the neuroleptic alpha-flupenthixol on latent inhibition in aversively- and appetitively-motivated paradigms: evidence for dopamine-reinforcer interactions. Psychopharmacology (Berl.), 115, 196-205.
108. Killcross, A. S., & Robbins, T.W. (1993). Differential effects of intra-accumbens and systemic amphetamine on latent inhibition using an on-baseline, within-subject conditioned suppression paradigm. Psychopharmacology (Berl.), 110, 479-489.
109. Kinon, B. J., & Lieberman, J. A. (1996). Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology (Berl.), 124, 2-34.
110. Krystal, J. H., Bennett, A., Abi-Saab, D., et al. (2000). Dissociation of ketamine effects on rule acquisition and rule implementation: possible relevance to NMDA receptor contributions to executive cognitive functions. Biological Psychiatry, 47, 137-143.
111. Krystal, J. H., D'Souza, D. C., Mathalon, D., et al. (2003). NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology (Berl.), 169, 215-233.
112. Kumari, V., Aasen, I., Ffytche, D., Williams, S. C., & Sharma, T. (2006). Neural correlates of adjunctive rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind fMRI study. Neuroimage, 29, 545-556.
113. Labrie, V., Lipina, T., & Roder, J. C. (2008). Mice with reduced NMDA receptor glycine affinity model some of the negative and cognitive symptoms of schizophrenia. Psychopharmacology (Berl.), 200, 217-230.
114. Lahti, A. C., Koffel, B., LaPorte, D., & Tamminga, C. A. (1995). Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology, 13, 9-19.
115. Laruelle, M., Abi-Dargham, A., Gil, R., Kegeles, L., & Innis, R. (1999). Increased dopamine transmission in schizophrenia: relationship to illness phases. Biological Psychiatry, 46, 56-72.
116. Laruelle, M., Abi-Dargham, A., van Dyck, C. H., et al. (1996). Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proceedings of the National Academy of Sciences of the United States of America, 93, 9235-9240.
117. Lee, S. W., Lee, J. G., Lee, B. J., & Kim, Y. H. (2007). A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia. International Clinical Psychopharmacology, 22, 63-68.
118. Levin, E. D., Bettegowda, C., Blosser, J., & Gordon, J. (1999). AR-R17779, and alpha7 nicotinic agonist, improves learning and memory in rats. Behavioural Pharmacology, 10, 675-680.
119. Leysen, J. E., Janssen, P.M., Schotte, A., Luyten, W. H., & Megens, A. A. (1993). Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors. Psychopharmacology (Berl.), 112(1 Suppl), S40-54.
120. Lieberman, J. A., Tollefson, G. D., Charles, C., et al. (2005). Antipsychotic drug effects on brain morphology in first-episode psychosis. Archives of General Psychiatry, 62, 361-370.
121. Lipina, T., Labrie, V., Weiner, I., & Roder, J. (2005). Modulators of the glycine site on NMDA receptors, D-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia. Psychopharmacology (Berl.), 179, 54-67.
122. Lipp, O. V., & Vaitl, D. (1992). Latent inhibition in human Pavlovian differential conditioning - effect of addiitional stimulation after preexposure and relation to schizotypal traits. Personality and Individual Differences, 13, 1003-1012.
123. Lubow, R. E. (2005). Construct validity of the animal latent inhibition model of selective attention deficits in schizophrenia. Schizophrenia Bulletin, 31, 139-153.
124. Lubow, R. E., & De la Casa, G. (2002). Latent inhibition as a function of schizotypality and gender: Implications for schizophrenia. Biological Psychiatry, 59, 69-86.
125. Lubow, R. E., Dressler, R., & Kaplan, O. (1999). The effects of target and distractor familiarity on visual search in de novo Parkinson's disease patients: latent inhibition and novel pop-out. Neuropsychology, 13, 415-423.
126. Lubow, R. E., Ingbergsachs, Y., Zalsteinorda, N., & Gewirtz, J. C. (1992). Latent inhibition in low and high "psychotic-prone" normal subjects. Personality and Individual Differences, 13, 563-572.
127. Lubow, R. E., Kaplan, O., Abramovich, P., Rudnick, A., & Laor, N. (2000). Visual search in schizophrenia: latent inhibition and novel pop-out effects. Schizophrenia Research, 45, 145-156.
128. Lubow, R. E., Kaplan, O., & De la Casa, G. (2001). Performance on the visual search analog of latent inhibition is modulated by an interaction between schizotypy and gender. Schizophrenia Research, 52, 275-287.
129. Lyon, M. (1991). Animal models of mania and schizophrenia. In P. Willner (Ed.), Behavioral Models in Psychopharmacology: Theoretical, Industrial and Clinical Perspectives. Cambridge: Cambridge University Press, pp. 253-310.
130. Malhotra, A. K., Adler, C.M., Kennison, S. D., et al. (1997). Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: a study with ketamine. Biological Psychiatry, 42, 664-668.
131. Malhotra, A. K., Pinals, D. A., Adler, C.M., et al. (1997). Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neurolepticfree schizophrenics. Neuropsychopharmacology, 17, 141-150.
132. Marder, S. R., & Fenton, W. (2004). Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophrenia Research, 72, 5-9.
133. Marino, M. J., Rouse, S. T., Levey, A. I., Potter, L. T., & Conn, P. J. (1998). Activation of the genetically defined m1 muscarinic receptor potentiates N-methyl-D-aspartate (NMDA) receptor currents in hippocampal pyramidal cells. Proceedings of the National Academy of Sciences of the United States of America, 95, 11465-11470.
134. Martin, L. F., Kem, W. R., & Freedman, R. (2004). Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia. Psychopharmacology (Berl.) 174, 54-64.
135. Masson, S., Avanzi, V., Troncoso, A. C., & Brandao, M. L. (2003). Effects of apomorphine and clozapine on conditioned freezing and latent inhibition. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 27, 935-943.
136. Mastropaolo, J., Rosse, R. B., & Deutsch, S. I. (2004). Anabasine, a selective nicotinic acetylcholine receptor agonist, antagonizes MK-801-elicited mouse popping behavior, an animal model of schizophrenia. Behavioural Brain Research, 153, 419-422.
137. Mathur, A., Shandarin, A., LaViolette, S. R., Parker, J., & Yeomans, J. S. (1997). Locomotion and stereotypy induced by scopolamine: contributions of muscarinic receptors near the pedunculopontine tegmental nucleus. Brain Research, 775, 144-155.
138. McCartan, D., Bell, R., Green, J. F., et al. (2001). The differential effects of chlorpromazine and haloperidol on latent inhibition in healthy volunteers. Journal of Psychopharmacology, 15, 96-104.
139. Meltzer, H. Y., & Nash, J. F. (1991). Effects of antipsychotic drugs on serotonin receptors. Pharmacological Reviews, 43, 587-604.
140. Meltzer, H. Y., & Sumiyoshi, T. (2003). Atypical antipsychotic drugs improve cognition in schizophrenia. Biological Psychiatry, 53, 265-267; author reply 267-268.
141. Millan, M. J. (2002). N-methyl-D-aspartate receptor-coupled glycineB receptors in the pathogenesis and treatment of schizophrenia: a critical review. Current Drug Targets. CNS and Neurological Disorders, 1, 191-213.
142. Millan, M. J. (2005). N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives. Psychopharmacology (Berl.), 179, 30-53.
143. Millan, M. J., Brocco, M., Gobert, A., et al. (1999). Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine versus amphetamine: importance of nucleus accumbens 5-HT2A sites for PCP-induced locomotion in the rat. The European Journal of Neuroscience, 11, 4419-4432.
144. Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005). Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Molecular Psychiatry, 10, 79-104.
145. Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997). Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. The Journal of Neuroscience, 17(8), 2921-2927.
146. Moghaddam, B., & Jackson, M. E. (2003). Glutamatergic animal models of schizophrenia. Annals of the New York Academy of Sciences, 1003, 131-137.
147. Moller, H. J. (2003). Management of the negative symptoms of schizophrenia: New treatment options. CNS Drugs, 17, 793-823.
148. Moran, P. M., Fischer, T. R., Hitchcock, J. M., & Moser, P. C. (1996). Effects of clozapine on latent inhibition in the rat. Behavioural Pharmacology, 7, 42-48.
149. Moser, P. C., Hitchcock, J. M., Lister, S., & Moran, P. M. (2000). The pharmacology of latent inhibition as an animal model of schizophrenia. Brain Research. Brain Research Reviews, 33, 275-307.
150. Murphy, C. A., Di Iorio, L., & Feldon, J. (2001). Effects of psychostimulant withdrawal on latent inhibition of conditioned active avoidance and prepulse inhibition of the acoustic startle response. Psychopharmacology (Berl.), 156, 155-164.
151. Nogue, S., Sanz, P., Munne, P., & de la Torre, R. (1991). Acute scopolamine poisoning after sniffing adulterated cocaine. Drug and Alcohol Dependence, 27, 115-116.
152. Noren, U., Bjorner, A., Sonesson, O., & Eriksson, L. (2006). Galantamine added to antipsychotic treatment in chronic schizophrenia: cognitive improvement? Schizophrenia Research, 85, 302-304.
153. Ogura, C., Kishimoto, A., & Nakao, T. (1976). Clinical effect of L-dopa on schizophrenia. Current Therapeutic Research, Clinical and Experimental, 20, 308-318.
154. Ohno, M., & Watanabe, S. (1996). D-cycloserine, a glycine site agonist, reverses working memory failure by hippocampal muscarinic receptor blockade in rats. European Journal of Pharmacology, 318, 267-271.
155. Olincy, A., Harris, J. G., Johnson, L. L., et al. (2006). Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Archives of General Psychiatry, 63, 630-638.
156. Olincy, A., & Stevens, K. E. (2007). Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men. Biochemical Pharmacology, 74, 1192-1201.
157. Palsson, E., Klamer, D., Wass, C., et al. (2005). The effects of phencyclidine on latent inhibition in taste aversion conditioning: differential effects of preexposure and conditioning. Behavioural Brain Research, 157, 139-146.
158. Payne, R. W. (1966). The measurement and significance of overinclusive thinking and retardation in schizophrenic patients. In P. Hoch & J. Zubin (Eds.), Psychopathology of Schizophrenia. New York: Grune and Stratton.
159. Pennartz, C.M., Groenewegen, H. J., & Lopes da Silva, F. H. (1994). The nucleus accumbens as a complex of functionally distinct neuronal ensembles: an integration of behavioural, electrophysiological and anatomical data. Progress in Neurobiology, 42, 719-761.
160. Perry, P. J., Wilding, D. C., & Juhl, R. P. (1978). Anticholinergic psychosis. American Journal of Hospital Pharmacy, 35, 725-728.
161. Peters, S. L., & Joseph, M. H. (1993). Haloperidol potentiation of latent inhibition in rats: evidence for a critical role at conditioning rather than pre-exposure. Behavioural Pharmacology, 4, 183-186.
162. Pichat, P., Bergis, O. E., Terranova, J. P., et al. (2007). SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia. Neuropsychopharmacology, 32, 17-34.
163. Powell, S. B., & Geyer, M. A. (2007). Overview of animal models of schizophrenia. Current Protocols in Neuroscience. Chapter 9, Unit 9, 24.
164. Ragozzino, M. E., Jih, J., & Tzavos, A. (2002). Involvement of the dorsomedial striatum in behavioral flexibility: role of muscarinic cholinergic receptors. Brain Research, 953, 205-214.
165. Ransom, R. W., & Deschenes, N. L. (1989). Glycine modulation of NMDA-evoked release of [3H]acetylcholine and [3H]dopamine from rat striatal slices. Neuroscience Letters, 96, 323-328.
166. Rapin, I., & Katzman, R. (1998). Neurobiology of autism. Annals of Neurology, 43, 7-14.
167. Rascle, C., Mazas, O., Vaiva, G., et al. (2001). Clinical features of latent inhibition in schizophrenia. Schizophrenia Research, 51, 149-161.
168. Rezvani, A. H., & Levin, E. D. (2003). Nicotinic-glutamatergic interactions and attentional performance on an operant visual signal detection task in female rats. European Journal of Pharmacology, 465, 83-90.
169. Robbins, T. W. (1991). Cognitive deficits in schizophrenia and Parkinson's disease - neural basis and the role of dopamine. In P. J.Willner & J. Scheel-Kruger (Eds.), The Mesolimbic Dopamine System - From Motivation to Action. Chichester: Wiley.
170. Robinson, G. B., Port, R. L., & Stillwell, E. G. (1993). Latent inhibition of the classically conditioned rabbit nictitating membrane response is unaffected by the NMDA antagonist MK-801. Psychobiology, 21, 120-124.
171. Rochford, J., Sen, A. P., & Quirion, R. (1996). Effect of nicotine and nicotinic receptor agonists on latent inhibition in the rat. The Journal of Pharmacology and Experimental Therapeutics, 277, 1267-1275.
172. Ruob, C., Elsner, J., Weiner, I., & Feldon, J. (1997). Amphetamine-induced disruption and haloperidol-induced potentiation of latent inhibition depend on the nature of the stimulus. Behavioural Brain Research, 88, 35-41.
173. Russig, H., Kovacevic, A., Murphy, C. A., & Feldon, J. (2003). Haloperidol and clozapine antagonise amphetamine-induced disruption of latent inhibition of conditioned taste aversion. Psychopharmacology (Berl.), 170, 263-270.
174. Russig, H., Murphy, C. A., & Feldon, J. (2002). Clozapine and haloperidol reinstate latent inhibition following its disruption during amphetamine withdrawal. Neuropsychopharmacology, 26, 765-777.
175. Salgado, J. V., Hetem, L. A., Vidal, M., Graeff, F. G., Danion, J. M., & Sandner, G. (2000). Reduction of latent inhibition by D-amphetamine in a conditioned suppression paradigm in humans. Behavioural Brain Research, 117, 61-67.
176. Sams-Dodd, F. (1996). Phencyclidine-induced stereotyped behaviour and social isolation in rats: a possible animal model of schizophrenia. Behavioural Pharmacology, 7, 3-23.
177. Sanfilipo, M., Wolkin, A., Angrist, B., et al. (1996). Amphetamine and negative symptoms of schizophrenia. Psychopharmacology (Berl.), 123, 211-214.
178. Sarter, M., Bruno, J. P., & Givens, B. (2003). Attentional functions of cortical cholinergic inputs: what does it mean for learning and memory? Neurobiology of Learning and Memory, 80, 245-256.
179. Sarter, M., Nelson, C. L., & Bruno, J. P. (2005). Cortical cholinergic transmission and cortical information processing in schizophrenia. Schizophrenia Bulletin, 31, 117-138.
180. Schotte, A., Janssen, P. F., Gommeren, W., et al. (1996). Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl.), 124, 57-73.
181. Schubert, M. H., Young, K. A., & Hicks, P. B. (2006). Galantamine improves cognition in schizophrenic patients stabilized on risperidone. Biological Psychiatry, 60, 530-533.
182. Shadach, E., Feldon, J., & Weiner, I. (1999). Clozapine-induced potentiation of latent inhibition is due to its action in the conditioning stage: implications for the mechanism of action of antipsychotic drugs. The International Journal of Neuropsychopharmacology, 2, 283-291.
183. Shadach, E., Gaisler, I., Schiller, D., & Weiner, I. (2000). The latent inhibition model dissociates between clozapine, haloperidol, and ritanserin. Neuropsychopharmacology, 23, 151-161.
184. Shakow, D. (1962). Segmental set. Archives of General Psychiatry, 6, 1-17.
185. Shannon, H. E., & Peters, S. C. (1990). A comparison of the effects of cholinergic and dopaminergic agents on scopolamine-induced hyperactivity in mice. The Journal of Pharmacology and Experimental Therapeutics, 255, 549-553.
186. Shannon, H. E., Rasmussen, K., Bymaster, F. P., et al. (2000). Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice. Schizophrenia Research, 42, 249-259.
187. Sirvio, J., Ekonsalo, T., Riekkinen, P., Jr., Lahtinen, H., & Riekkinen, P., Sr. (1992). D-cycloserine, a modulator of the N-methyl-D-aspartate receptor, improves spatial learning in rats treated with muscarinic antagonist. Neuroscience Letters, 146, 215-218.
188. Smith, A., Li, M., Becker, S., & Kapur, S. (2006). Dopamine, prediction error and associative learning: a model-based account. Network, 17, 61-84.
189. Soffie, M., & Lamberty, Y. (1987). Scopolamine disrupts visual reversal without affecting the first discrimination. Physiology and Behavior, 40, 263-265.
190. Solomon, P. R., Crider, A., Winkelman, J. W., et al. (1981). Disrupted latent inhibition in the rat with chronic amphetamine or haloperidol-induced supersensitivity: relationship to schizophrenic attention disorder. Biological Psychiatry, 16, 519-537.
191. Stanhope, K. J., Mirza, N. R., Bickerdike, M. J., et al. (2001). The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat. The Journal of Pharmacology and Experimental Therapeutics, 299, 782-792.
192. Stone, W. S., Rudd, R. J., & Gold, P. E. (1990). Glucose and physostigmine effects on morphine- and amphetamine-induced increases in locomotor activity in mice. Behavioral and Neural Biology, 54, 146-155.
193. Svensson, T. H. (2000). Dysfunctional brain dopamine systems induced by psychotomimetic NMDA-receptor antagonists and the effects of antipsychotic drugs. Brain Research. Brain Research Reviews, 31, 320-329.
194. Swerdlow, N. R., Braff, D. L., Hartston, H., Perry, W., & Geyer, M. A. (1996). Latent inhibition in schizophrenia. Schizophrenia Research, 20, 91-103.
195. Swerdlow, N. R., Hartston, H. J., & Hartman, P. L. (1999). Enhanced visual latent inhibition in obsessive-compulsive disorder. Biological Psychiatry, 45, 482-488.
196. Swerdlow, N. R., & Koob, G. F. (1987). Dopamine, schizophrenia, mania and depression: toward a unified hypothesis of cortico-striato-pallido-thalamic function. Behavioral and Brain Sciences, 10, 197-245.
197. Swerdlow, N. R., Stephany, N., Wasserman, L. C., et al. (2003). Dopamine agonists disrupt visual latent inhibition in normal males using a within-subject paradigm. Psychopharmacology (Berl.), 169, 314-320.
198. Swerdlow, N. R., Stephany, N., Wasserman, L. C., et al. (2005). Intact visual latent inhibition in schizophrenia patients in a within-subject paradigm. Schizophrenia Research, 72, 169-183.
199. Tamminga, C. A. (1998). Schizophrenia and glutamatergic transmission. Critical Reviews in Neurobiology, 12, 21-36.
200. Tanii, Y., Nishikawa, T., Hashimoto, A., & Takahashi, K. (1994). Stereoselective antagonism by enantiomers of alanine and serine of phencyclidine-induced hyperactivity, stereotypy and ataxia in the rat. The Journal of Pharmacology and Experimental Therapeutics, 269, 1040-1048.
201. Tenn, C. C., Fletcher, P. J., & Kapur, S. (2005a). A putative animal model of the "prodromal" state of schizophrenia. Biological Psychiatry, 57, 586-593.
202. Tenn, C. C., Kapur, S., & Fletcher, P. J. (2005b). Sensitization to amphetamine, but not phencyclidine, disrupts prepulse inhibition and latent inhibition. Psychopharmacology (Berl.), 180, 366-376.
203. Thornton, J. C., Dawe, S., Lee, C., et al. (1996). Effects of nicotine and amphetamine on latent inhibition in human subjects. Psychopharmacology (Berl.), 127, 164-173.
204. Timmermann, D. B., Gronlien, J. H., Kohlhaas, K. L., et al. (2007). An allosteric modulator of the alpha7 nicotinic acetylcholine receptor possessing cognitionenhancing properties in vivo. The Journal of Pharmacology and Experimental Therapeutics, 323, 294-307.
205. Tinsley, M. R., Quinn, J. J., & Fanselow, M. S. (2004). The role of muscarinic and nicotinic cholinergic neurotransmission in aversive conditioning: comparing pavlovian fear conditioning and inhibitory avoidance. Learning and Memory, 11, 35-42.
206. Toda, M., & Abi-Dargham, A. (2007). Dopamine hypothesis of schizophrenia: Making sense of it all. Current Psychiatry Reports, 9, 329-336.
207. Toth, E., & Lajtha, A. (1986). Antagonism of phencyclidine-induced hyperactivity by glycine in mice. Neurochemical Research, 11, 393-400.
208. Trimble, K. M., Bell, R., & King, D. J. (1997). Enhancement of latent inhibition in the rat by the atypical antipsychotic agent remoxipride. Pharmacology, Biochemistry, and Behavior, 56, 809-816.
209. Trimble, K. M., Bell, R., & King, D. J. (1998). Enhancement of latent inhibition in the rat at a high dose of clozapine. Journal of Psychopharmacology, 12, 215-219.
210. Trimble, K.M., Bell, R., & King, D. J. (2002). Effects of the selective dopamine D(1) antagonists NNC 01-0112 and SCH 39166 on latent inhibition in the rat. Physiology and Behavior, 77, 115-123.
211. Turgeon, S.M., Auerbach, E. A., Duncan-Smith, M. K., George, J. R., & Graves, W.W. (2000). The delayed effects of DTG and MK-801 on latent inhibition in a conditioned taste-aversion paradigm. Pharmacology, Biochemistry, and Behavior, 66, 533-539.
212. Turgeon, S.M., Auerbach, E. A., & Heller, M. A. (1998). The delayed effects of phencyclidine (PCP) disrupt latent inhibition in a conditioned taste aversion paradigm. Pharmacology, Biochemistry, and Behavior, 60, 553-558.
213. Ukai, M., Okuda, A., & Mamiya, T. (2004). Effects of anticholinergic drugs selective for muscarinic receptor subtypes on prepulse inhibition in mice. European Journal of Pharmacology, 492, 183-187.
214. Vaitl, D., Lipp, O., Bauer, U., et al. (2002). Latent inhibition and schizophrenia: Pavlovian conditioning of autonomic responses. Schizophrenia Research, 55, 147-158.
215. Vaitl, D., & Lipp, O. V. (1997). Latent inhibition and autonomic responses: a psychophysiological approach. Behavioural Brain Research, 88, 85-93.
216. van der Meulen, J. A., Bilbija, L., Joosten, R. N., de Bruin, J. P., & Feenstra, M. G. (2003). The NMDA-receptor antagonist MK-801 selectively disrupts reversal learning in rats. Neuroreport, 14, 2225-2228.
217. Viu, E., Zapata, A., Capdevila, J., Skolnick, P., & Trullas, R. (2000). Glycine(B) receptor antagonists and partial agonists prevent memory deficits in inhibitory avoidance learning. Neurobiology of Learning and Memory, 74, 146-160.
218. Warburton, E. C., Joseph, M. H., Feldon, J., Weiner, I., & Gray, J. A. (1994). Antagonism of amphetamine-induced disruption of latent inhibition in rats by haloperidol and ondansetron: implications for a possible antipsychotic action of ondansetron. Psychopharmacology (Berl.), 114, 657-664.
219. Weiner, I. (1990). Neural substrates of latent inhibition: the switching model. Psychological Bulletin, 108, 442-461.
220. Weiner, I. (2003). The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment. Psychopharmacology (Berl.), 169, 257-297.
221. Weiner, I., Bernasconi, E., Broersen, L. M., & Feldon, J. (1997a). Amphetamineinduced disruption of latent inhibition depends on the nature of the stimulus. Behavioural Pharmacology, 8, 442-457.
222. Weiner, I., & Feldon, J. (1987). Facilitation of latent inhibition by haloperidol in rats. Psychopharmacology (Berl.), 91, 248-253.
223. Weiner, I., & Feldon, J. (1992). Phencyclidine does not disrupt latent inhibition in rats: Implications for animal models of schizophrenia. Pharmacology, Biochemistry, and Behavior, 42, 625-631.
224. Weiner, I., & Feldon, J. (1997). The switching model of latent inhibition: an update of neural substrates. Behavioural Brain Research, 88, 11-25.
225. Weiner, I., Feldon, J., & Katz, Y. (1987). Facilitation of the expression but not the acquisition of latent inhibition by haloperidol in rats. Pharmacology, Biochemistry, and Behavior, 26, 241-246.
226. Weiner, I., Izraeli-Telerant, A., & Feldon, J. (1987). Latent inhibition is not affected by acute or chronic administration of 6 mg/kg dl-amphetamine. Psychopharmacology (Berl.), 91, 345-351.
227. Weiner, I., & Joel, D. (2002). Dopamine in schizophrenia: dysfunctional information processing in basal ganglia-thalamocortical split circuits. In G. Di Chiara (Ed.), Handbook of Experimental Pharmacology, vol. 54/II, Dopamine in the CNS II. Berlin: Springer, pp. 418-472.
228. Weiner, I., Lubow, R. E., & Feldon, J. (1981). Chronic amphetamine and latent inhibition. Behavioural Brain Research, 2, 285-286.
229. Weiner, I., Lubow, R. E., & Feldon, J. (1984). Abolition of the expression but not the acquisition of latent inhibition by chronic amphetamine in rats. Psychopharmacology (Berl.), 83, 194-199.
230. Weiner, I., Lubow, R. E., & Feldon, J. (1988). Disruption of latent inhibition by acute administration of low doses of amphetamine. Pharmacology, Biochemistry, and Behavior, 30, 871-878.
231. Weiner, I., Shadach, E., Barkai, R., & Feldon, J. (1997b). Haloperidol- and clozapine-induced enhancement of latent inhibition with extended conditioning: Implications for the mechanism of action of neuroleptic drugs. Neuropsychopharmacology, 16, 42-50.
232. Weiner, I., Shadach, E., Tarrasch, R., Kidron, R., & Feldon, J. (1996). The latent inhibition model of schizophrenia: further validation using the atypical neuroleptic, clozapine. Biological Psychiatry, 40, 834-843.
233. Weiner, I., Shofel, A., & Feldon, J. (1990). Disruption of latent inhibition by low dose of amphetamine is antagonized by haloperidol and apomorphine. Journal of Psychopharmacology, 4, 255.
234. Weiner, I., Tarrasch, R., Bernasconi, E., et al. (1997c). Amphetamine-induced disruption of latent inhibition is not reinforcer-mediated. Pharmacology, Biochemistry, and Behavior, 56, 817-826.
235. Williams, J. H., Wellman, N. A., Geaney, D. P., et al. (1996). Antipsychotic drug effects in a model of schizophrenic attentional disorder: a randomized controlled trial of the effects of haloperidol on latent inhibition in healthy people. Biological Psychiatry, 40, 1135-1143.
236. Williams, J. H., Wellman, N. A., Geaney, D. P., et al. (1997). Haloperidol enhances latent inhibition in visual tasks in healthy people. Psychopharmacology (Berl.), 133, 262-268.
237. Wishka, D. G., Walker, D. P., Yates, K. M., et al. (2006). Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure-activity relationship. Journal of Medicinal Chemistry, 49, 4425-4436.
238. Wolkin, A., Sanfilipo, M., Wolf, A. P., Angrist, B., Brodie, J. D., & Rotrosen, J. (1992). Negative symptoms and hypofrontality in chronic schizophrenia. Archives of General Psychiatry, 49, 959-965.
239. Zuckerman, L., Rimmerman, N., & Weiner, I. (2003). Latent inhibition in 35-day-old rats is not an "adult" latent inhibition: implications for neurodevelopmental models of schizophrenia. Psychopharmacology (Berl.), 169, 298-307.
240. Zuckerman, L., & Weiner, I. (2005). Maternal immune activation leads to behavioral and pharmacological changes in the adult offspring. Journal of Psychiatric Research, 39, 311-323.